SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Brian P. who wrote (6933)2/6/1999 10:39:00 AM
From: Anthony Wong  Respond to of 9523
 
Brian, from a Merrill Lynch 2/1 Report "Celebrex - Strong out of the Box":

Merck's Vioxx, which is currently under priority review with the FDA, could be approved by May 23 rd. Celebrex is indicated for osteo- and rheumatoid arthritis, while Merck is seeking indication for osteoarthritis and pain for Vioxx.

P.S. Merck submitted the application for Vioxx on Nov. 23, 1998.
If approved, most analysts expect the drug to be available in June.

Message 7631381



To: Brian P. who wrote (6933)2/6/1999 5:46:00 PM
From: BigKNY3  Read Replies (1) | Respond to of 9523
 
Vioxx was given priority review by the FDA. Accordingly, it should be on the market anywhere form May to July, 1999.

BigKNY3


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News